Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Cash & Equivalents (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Cash & Equivalents for 10 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 75.01% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, down 75.01% year-over-year, with the annual reading at $3.2 million for FY2025, 75.01% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $3.2 million at Rein Therapeutics, down from $4.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $21.9 million in Q2 2024, with the low at $3.2 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $10.1 million, with a median of $7.7 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents surged 233.81% in 2023, then crashed 77.07% in 2025.
  • Over 5 years, Cash & Equivalents stood at $3.6 million in 2021, then soared by 44.28% to $5.2 million in 2022, then soared by 233.81% to $17.3 million in 2023, then fell by 25.8% to $12.9 million in 2024, then tumbled by 75.01% to $3.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $3.2 million, $4.0 million, and $5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.